

# Brian C Case

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/170203/publications.pdf>

Version: 2024-02-01

97  
papers

776  
citations

687220

13  
h-index

642610

23  
g-index

98  
all docs

98  
docs citations

98  
times ranked

871  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Left Ventricular Outflow Tract Calcification on Outcomes Following Transcatheter Aortic Valve Replacement. <i>Cardiovascular Revascularization Medicine</i> , 2022, 35, 1-7.	0.3	6
2	Prosthetic valve endocarditis after transcatheter aortic valve replacement in <sc>lowâ€risk</sc> patients. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 896-903.	0.7	4
3	Impact of Left Ventricular Outflow Tract Calcium on Hemodynamics and Outcomes in Patients After Transcatheter Aortic Valve Implantation With a Contemporary Self-Expanding Valve. <i>American Journal of Cardiology</i> , 2022, 168, 128-134.	0.7	1
4	Exploiting the Transformation Temperature to Reform an Infolded Nitinol Self-Expanding Peripheral Stent. <i>Journal of Endovascular Therapy</i> , 2022, , 152660282110687.	0.8	0
5	Overview of FDA Circulatory System Devices Panel virtual meeting on TriGUARD 3 cerebral embolic protection. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1789-1795.	0.7	3
6	Overview of the FDA's Circulatory System Devices Panel virtual meeting on the TransMedics Organ Care System (OCS) Heart â€ portable extracorporeal heart perfusion and monitoring system. <i>American Heart Journal</i> , 2022, 247, 90-99.	1.2	6
7	COVID-19 pandemic and acute myocardial infarction: Don't ignore chest pain. <i>Cardiovascular Revascularization Medicine</i> , 2022, , .	0.3	0
8	Postoperative myocardial injury and outcomes in liver and kidney transplant patients. <i>Cardiovascular Revascularization Medicine</i> , 2022, , .	0.3	6
9	Implications of COVID-19 Vaccination on Hospital Encounters and Outcomes. <i>American Journal of Cardiology</i> , 2022, 170, 105-111.	0.7	3
10	The Need for Additional Phenotyping When Defining Cardiogenic Shock. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 890-895.	1.1	1
11	Lipid-rich plaque density and low-density lipoprotein cholesterol in statin-treated versus statin-na&uml;ve patients: a post hoc analysis of the LRP study. <i>EuroIntervention</i> , 2022, 18, 91-93.	1.4	2
12	Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study. <i>EuroIntervention</i> , 2022, 18, e407-e416.	1.4	15
13	Sex Disparities in Hemodynamics and Outcomes in Patients Who Underwent Contemporary Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2022, 174, 101-106.	0.7	3
14	Usefulness of Temporary Pacing in Patients With New Left Bundle Branch Block During Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2022, , .	0.7	0
15	Treatment of a Heavily Calcified Celiac Artery Ostial Subtotal Occlusion Using Shockwave Lithotripsy: A Novel Approach. <i>Cardiovascular Revascularization Medicine</i> , 2021, 25, 72-74.	0.3	3
16	Adverse Events and Modes of Failure Related to Rotational Atherectomy System: The Utility of the MAUDE Database. <i>Cardiovascular Revascularization Medicine</i> , 2021, 27, 57-62.	0.3	4
17	Review of PCR e-Course 2020 Late-Breaking Clinical Trials. <i>Cardiovascular Revascularization Medicine</i> , 2021, 27, 67-70.	0.3	0
18	Review of Structural Late-Breaking Trials From the TVT Connect 2020 and PCR e-Course 2020 Virtual Meetings. <i>Cardiovascular Revascularization Medicine</i> , 2021, 27, 71-78.	0.3	2

#	ARTICLE	IF	CITATIONS
19	Micropuncture technique for femoral access is associated with lower vascular complications compared to standard needle. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1379-1385.	0.7	28
20	Intravascular ultrasound guidance in the evaluation and treatment of left main coronary artery disease. <i>International Journal of Cardiology</i> , 2021, 325, 168-175.	0.8	8
21	Utility of Routine Invasive Coronary Angiography Prior to Transcatheter Aortic Valve Replacement. <i>Cardiovascular Revascularization Medicine</i> , 2021, 26, 1-5.	0.3	4
22	Treatment of Patients With Recurrent Coronary In-stent Restenosis With Failed Intravascular Brachytherapy. <i>American Journal of Cardiology</i> , 2021, 142, 44-51.	0.7	1
23	Optical Coherence Tomography based treatment approach for patients with Acute Coronary Syndrome. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 141-149.	0.6	1
24	Cases of Early, Aggressive In-Stent Restenosis in Left Main Double Kissing (DK) Crush Technique and Treatment Options. <i>Cardiovascular Revascularization Medicine</i> , 2021, 27, 90-94.	0.3	0
25	National trends and 30-day readmission rates for next-day-discharge transcatheter aortic valve replacement: An analysis from the Nationwide Readmissions Database, 2012-2016. <i>American Heart Journal</i> , 2021, 231, 25-31.	1.2	8
26	Return of the Left Internal Mammary Artery. <i>Cardiovascular Revascularization Medicine</i> , 2021, 23, 119-120.	0.3	0
27	LAMPOON techniques to prevent or manage left ventricular outflow tract obstruction in transcatheter mitral valve replacement. <i>Annals of Cardiothoracic Surgery</i> , 2021, 10, 172-179.	0.6	16
28	Right transradial coronary angiography in the setting of tortuous brachiocephalic/thoracic aorta (‘‘elephant head’’): Impact on fluoroscopy time and contrast use. <i>Catheterization and Cardiovascular Interventions</i> , 2021, , .	0.7	1
29	Intravascular Lithotripsyâ€‘Facilitated Carotid Interventions. <i>Journal of Endovascular Therapy</i> , 2021, 28, 486-486.	0.8	0
30	<sc>Realâ€‘world</sc> experience of <sc>sutureâ€‘based</sc> closure devices: Insights from the <sc>FDA</sc> Manufacturer and User Facility Device Experience. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 572-577.	0.7	11
31	Rescue alcohol septal ablation for dynamic left ventricular outflow tract obstruction and haemodynamic collapse after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2021, 42, 2955.	1.0	0
32	Tip-to-Base LAMPOON for Transcatheter Mitral Valve Replacement With a Protected Mitral Annulus. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 541-550.	1.1	17
33	Clinical Impact and Predictors of Troponin Elevation in Patients With COVID-19. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 41-44.	0.3	11
34	The challenges of coronary noâ€‘reflow phenomenon. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 612-613.	0.7	3
35	Comparison of Characteristics and Outcomes of Patients With Acute Myocardial Infarction With Versus Without Coronarvirus-19. <i>American Journal of Cardiology</i> , 2021, 144, 8-12.	0.7	25
36	Pericardiocentesis induced right ventricular changes in patients with and without pulmonary hypertension. <i>Echocardiography</i> , 2021, 38, 752-759.	0.3	2

#	ARTICLE	IF	CITATIONS
37	Balloon-Expandable Valve Geometry After Transcatheter Aortic Valve Replacement in Low-Risk Patients With Bicuspid Versus Tricuspid Aortic Stenosis. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 7-12.	0.3	7
38	A patient-level, pooled analysis of mortality rates with the Paseo-18 Lux paclitaxel drug-coated balloon in peripheral arterial disease. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 49-54.	0.3	1
39	Initial Findings From the North American COVID-19 Myocardial Infarction Registry. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1994-2003.	1.2	96
40	The impact of COVID-19 patients with troponin elevation on renal impairment and clinical outcome. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 45-48.	0.3	1
41	<scp>Propensityâ€matched</scp> comparison of <scp>largeâ€bore</scp> access closure in transcatheter aortic valve replacement using <scp>MANTA</scp> versus Perclose: A <scp>realâ€world</scp> experience. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 580-585.	0.7	11
42	Reasons for Screen Failure for Transcatheter Mitral Valve Repair and Replacement. <i>American Journal of Cardiology</i> , 2021, 148, 130-137.	0.7	12
43	Waksman In-Stent Restenosis Classification: A Mechanism-Based Approach to the Treatment of Restenosis. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 62-67.	0.3	11
44	Overview of the Virtual 2021 FDAâ€™s Circulatory System Devices Advisory Panel on Lutonix 014 Drug-Coated Percutaneous Transluminal Angioplasty Catheter for Below-the-Knee Lesions in Critical Limb Ischemia. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 55-61.	0.3	3
45	Pre-Operative Cardiovascular Testing before Liver Transplantation. <i>American Journal of Cardiology</i> , 2021, 152, 132-137.	0.7	3
46	The Impact of Aortic Angulation on Contemporary Transcatheter Aortic Valve Replacement Outcomes. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1209-1215.	1.1	7
47	Feasibility and Safety of High-Risk Percutaneous Coronary Intervention Without Mechanical Circulatory Support. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009960.	1.4	10
48	Usefulness of Antiplatelet Therapy After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2021, 149, 57-63.	0.7	0
49	Real-World Experience of the MANTA Closure Device: Insights From the FDA Manufacturer and User Facility Device Experience (MAUDE) Database. <i>Cardiovascular Revascularization Medicine</i> , 2021, 27, 63-66.	0.3	5
50	Transcatheter Aortic Valve Replacement in Low-Risk Bicuspid and Tricuspid Patients: Meta-Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2021, 33, 1-6.	0.3	6
51	Transcatheter Versus Surgical Aortic Valve Replacement in Young, Low-Risk Patients With Severe Aortic Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1169-1180.	1.1	30
52	One-Year Outcomes After Treatment of Ostial In-Stent Restenosis in Left Circumflex Versus Left Anterior Descending or Right Coronary Artery. <i>American Journal of Cardiology</i> , 2021, 151, 45-50.	0.7	3
53	Review of Imaging and Physiology Late Breaking Trials From the TCT Connect 2020 Virtual Meeting. <i>Cardiovascular Revascularization Medicine</i> , 2021, 28, 71-75.	0.3	0
54	Review of Structural Late Breaking Trials From the TCT Connect 2020 Virtual Meeting. <i>Cardiovascular Revascularization Medicine</i> , 2021, 28, 76-81.	0.3	0

#	ARTICLE	IF	CITATIONS
55	Review of Late-Breaking Trials From CRT 2021 Virtual. Cardiovascular Revascularization Medicine, 2021, 28, 3-8.	0.3	0
56	Review of Coronary Late Breaking Trials From the TCT Connect 2020 Virtual Meeting. Cardiovascular Revascularization Medicine, 2021, 28, 65-70.	0.3	0
57	Comparison of Outcomes in Patients With COVID-19 and Thrombosis Versus Those Without Thrombosis. American Journal of Cardiology, 2021, 160, 106-111.	0.7	4
58	Complications of Late-Presenting Myocardial Infarction in a COVID-19 Patient. Cardiovascular Revascularization Medicine, 2021, 29, 100-101.	0.3	0
59	High-Risk Percutaneous Coronary Intervention of Native Coronary Arteries Without Mechanical Circulatory Support in Acute Coronary Syndrome Without Cardiogenic Shock. American Journal of Cardiology, 2021, 158, 37-44.	0.7	1
60	Single-Center Experience With the LOTUS Edge Transcatheter Heart Valve. Cardiovascular Revascularization Medicine, 2021, 29, 85-88.	0.3	3
61	Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. American Heart Journal, 2021, 238, 59-65.	1.2	2
62	Meta-Analysis of Usefulness of Antiplatelet Therapy in Ischemic Stroke or Transient Ischemic Attack. American Journal of Cardiology, 2021, 153, 129-134.	0.7	5
63	Review of Interventional Late Breaking Trials From AHA Scientific Sessions 2020 Virtual Meeting. Cardiovascular Revascularization Medicine, 2021, 29, 71-76.	0.3	0
64	Implications of Left Ventricular Function on Short-Term Outcomes in COVID-19 Patients With Myocardial Injury. Cardiovascular Revascularization Medicine, 2021, 29, 45-49.	0.3	5
65	Non-ST-Segment Elevation Myocardial Infarction: When Is Rapid Revascularization Critical?. Journal of the American Heart Association, 2021, 10, e023645.	1.6	2
66	Contemporary postmarketing adverse events and modes of failure related to VASCADE Vascular Closure System: The utility of the MAUDE database. Catheterization and Cardiovascular Interventions, 2021, , .	0.7	3
67	Evolution of Management and Outcomes of Patients with Myocardial Injury During the COVID-19 Pandemic. American Journal of Cardiology, 2021, 157, 42-47.	0.7	5
68	Early Leaflet Thickening, Durability and Bioprosthetic Valve Failure in TAVR. Interventional Cardiology Clinics, 2021, 10, 531-539.	0.2	0
69	Valve-in-Valve for Failing Mitral Bioprosthesis With Tip-to-Base LAMPOON to Prevent Left Ventricular Outflow Tract Obstruction. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2021, 16, 409-413.	0.4	2
70	Impact of baseline imaging of non-culprit coronary lesions and adverse events: Insight from LRP study. Cardiovascular Revascularization Medicine, 2021, , .	0.3	1
71	Resolution of Massive Intracoronary Thrombus During Percutaneous Coronary Intervention Utilizing Intensive Pharmacological and Aspiration Strategies. Cardiovascular Revascularization Medicine, 2020, 21, 251-253.	0.3	0
72	Real-World Experience of the Sentinel Cerebral Protection Device: Insights From the FDA Manufacturer and User Facility Device Experience (MAUDE) Database. Cardiovascular Revascularization Medicine, 2020, 21, 235-238.	0.3	14

#	ARTICLE	IF	CITATIONS
73	Procedural Outcomes of Patients Undergoing Percutaneous Coronary Intervention for De Novo Lesions in the Ostial and Proximal Left Circumflex Coronary Artery. <i>American Journal of Cardiology</i> , 2020, 135, 62-67.	0.7	9
74	One Valve Type Does Not Fit All. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 931.	0.3	0
75	Risk of Coronary Obstruction and Feasibility of Coronary Access After Repeat Transcatheter Aortic Valve Replacement With the Self-Expanding Evolut Valve. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009496.	1.4	38
76	Procedural Characteristics and Outcomes of Patients Undergoing Percutaneous Coronary Intervention During Normal Work Hours Versus Non-work Hours. <i>American Journal of Cardiology</i> , 2020, 135, 32-39.	0.7	1
77	Admissions Rate and Timing of Revascularization in the United States in Patients With Non-ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2020, 134, 24-31.	0.7	17
78	Optimizing Monotherapy Selection, Aspirin Versus P2Y12 Inhibitors, Following Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2020, 135, 154-165.	0.7	7
79	Review of CRT 2020 Late-breaking Trials. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 707-711.	0.3	1
80	MitraClip 30-Day Readmissions and Impact of Early Discharge: An Analysis from the Nationwide Readmissions Database 2016. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 954-958.	0.3	7
81	Tip-to-Base LAMPOON to Prevent Left Ventricle Outflow Tract Obstruction in Valve-in-Valve Transcatheter Mitral Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1126-1128.	1.1	12
82	Treatment of ST-Segment Elevation Myocardial Infarction During COVID-19 Pandemic. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1024-1029.	0.3	20
83	Review of ACC 2020 Late-Breaking Trials in Interventional Cardiology. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 905-911.	0.3	1
84	Guidelines for Balancing Priorities in Structural Heart Disease During the COVID-19 Pandemic. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1030-1033.	0.3	11
85	Intravascular Lithotripsy Facilitated Percutaneous Endovascular Intervention of the Aortic Arch: A Single-Center Experience. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1006-1015.	0.3	9
86	Drug-Coated Balloon for De Novo Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1061-1073.	1.2	96
87	The Orsiro Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stent: A Review of Current Evidence. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 540-548.	0.3	11
88	Risk of Mortality with Paclitaxel Drug-Coated Balloon in De Novo Coronary Artery Disease. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 549-555.	0.3	0
89	COVID-19 (SARS-CoV-2) and the Heart – An Ominous Association. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 946-949.	0.3	41
90	Bioresorbable Scaffolds: Current Technology and Future Perspectives. <i>Rambam Maimonides Medical Journal</i> , 2020, 11, e0016.	0.4	19

#	ARTICLE	IF	CITATIONS
91	The economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy. <i>Journal of Clinical Lipidology</i> , 2019, 13, 754-761.	0.6	10
92	Shared Decision Making in Cardiovascular Disease in the Outpatient Setting. <i>JACC: Case Reports</i> , 2019, 1, 261-270.	0.3	3
93	Pre-Operative Cardiovascular Testing and Post-Renal Transplant Clinical Outcomes. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 588-593.	0.3	8
94	Safety and Feasibility of Performing Pericardiocentesis on Patients with Significant Pulmonary Hypertension. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 1090-1095.	0.3	5
95	Comparison of coronary revascularization appropriateness for non-acute coronary syndrome cases under the 2017 update vs the 2012 appropriate use criteria. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 620-625.	0.7	0
96	Severe ischemic cardiomyopathy—a new answer in management?. <i>Annals of Translational Medicine</i> , 2016, 4, S46-S46.	0.7	0
97	Pulmonary Embolism Diagnosed From Right Heart Changes Seen After Exercise Stress Echocardiography. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, e003506.	1.3	2